Uncategorized
Aerie resubmits NDA for Rhopressa
Aerie Pharmaceuticals has resubmitted a new drug application for its once-daily IOP-lowering eye drop Rhopressa.The initial filing for Rhopressa (netarsudil ophthalmic solution 0.02%) was withdrawn in October 2016 because the contract manufacturer in Tampa, Florida, was not prepared for preapproval FDA inspection, according to a company press release.